Antibiotic resistance threatens the efficacy of prophylaxis

The Lancet Infectious Diseases

Volumn 15, Issue 12, 2015, Pages 1368-1369

  Wolf, Joshua ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL PRACTICE; COLORECTAL SURGERY; DRUG EFFICACY; HUMAN; INFECTION CONTROL; NONHUMAN; NOTE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; SURGICAL INFECTION; TREATMENT OUTCOME; TUMOR BIOPSY; ECONOMICS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; SURGICAL WOUND INFECTION;

ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; SURGICAL WOUND INFECTION;

EID: 84965085945     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00317-5     Document Type: Note

References (14)

1. 1 Teillant, A, Gandra, S, Barter, D, Morgan, DJ, Laxminarayan, R, Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a systematic review and modelling study. Lancet Infect Dis, 2015 published online Oct 16. http://dx.doi.org/10.1016/S1473-3099(15)00317-5.
2. 2 Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013, 2013, Centers for Disease Control and Prevention, Atlanta.
3. 3 Gafter-Gvili, A, Fraser, A, Paul, M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev, 1, 2012 CD004386.
4. 4 Nelson, RL, Gladman, E, Barbateskovic, M, Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev, 5, 2014 CD001181.
5. 5 Roberts, MJ, Williamson, DA, Hadway, P, Doi, SA, Gardiner, RA, Paterson, DL, Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents 43 (2014), 301–309.
6. 6 De Rosa, FG, Motta, I, Audisio, E, et al. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis, 13, 2013, 563.
7. 7 Higgins, J, Green, S, (eds.) Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0, 2011, The Cochrane Collaboration, London.
8. 8 R-GNOSIS project. Resistance in Gram-negative organisms: studying intervention strategies. http://www.r-gnosis.eu/, 2012 (accessed Aug 19, 2015).
9. 9 Horakova, M, Lubuska, L, Kolar, M, et al. Individualized prophylaxis in patients with esophageal replacement because of cancer. Surg Infect, 2015, 10.1089/sur.2014.132 published online Aug 3.
10. 10 Kirby, A, Bretsztajn, L, Santoni, N, Patel, H, Burke, D, Horner, C, Microbiological prediction of surgical site infection risk after colorectal surgery: a feasibility study. J Hosp Infect 90 (2015), 271–272.
11. 11 Cohen, ML, Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257 (1992), 1050–1055.
12. 12 WHO. Worldwide country situation analysis: response to antimicrobial resistance, 2015, World Health Organization, Geneva.
13. 13 Food and Drug Administration. Guidance for industry: new animal drugs and new animal drug combination products administered in or on medicated feed or drinking water of food-producing animals: recommendations for drug sponsors for voluntarily aligning product use conditions with GFI #209, 2013, Food and Drug Administration, Rockville, MD.
14. 14 Szymczak, JE, Feemster, KA, Zaoutis, TE, Gerber, JS, Pediatrician perceptions of an outpatient antimicrobial stewardship intervention. Infect Control Hosp Epidemiol 35:suppl 3 (2014), S69–S78.